Zobrazeno 1 - 10
of 1 385
pro vyhledávání: '"Jos. H. Beijnen"'
Autor:
Aristeidis Lentzas, Mark C. de Gooijer, Stefanie Zuidema, Amber Meurs, Ceren H. Çitirikkaya, Nikkie Venekamp, Jos H. Beijnen, Olaf van Tellingen
Publikováno v:
Fluids and Barriers of the CNS, Vol 21, Iss 1, Pp 1-15 (2024)
Abstract Background Pharmacotherapy for brain diseases is severely compromised by the blood-brain barrier (BBB). ABCB1 and ABCG2 are drug transporters that restrict drug entry into the brain and their inhibition can be used as a strategy to boost dru
Externí odkaz:
https://doaj.org/article/57eb6677d2ba47b88093983f8eec384d
Autor:
Lishi Lin, Aletta P. I. Houwink, Jolanda M. van Dieren, Esther K. Wolthuis, Johannes V. van Thienen, Michiel S. van der Heijden, John B. A. G. Haanen, Jos H. Beijnen, Alwin D. R. Huitema
Publikováno v:
Cancer Medicine, Vol 13, Iss 12, Pp n/a-n/a (2024)
Abstract Introduction Severe immune‐related adverse events (irAEs) due to immune checkpoint inhibitors (ICIs) can lead to admission to the intensive care unit (ICU). In this retrospective study, we determined the incidence, treatment patterns and s
Externí odkaz:
https://doaj.org/article/b377fea45b7f46209b1c0d057520a529
Autor:
Jamie Rijmers, Irene A. Retmana, Viët Bui, Davinia Arguedas, Maria C. Lebre, Rolf W. Sparidans, Jos H. Beijnen, Alfred H. Schinkel
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 175, Iss , Pp 116720- (2024)
Opnurasib (JDQ443) is a newly developed oral KRASG12C inhibitor, with a binding mechanism distinct from the registered KRASG12C inhibitors sotorasib and adagrasib. Phase I and II clinical trials for opnurasib in NSCLC are ongoing. We evaluated the ph
Externí odkaz:
https://doaj.org/article/aee126997e694d2fb3116e085d0ab755
Autor:
Wenlong Li, Rolf W. Sparidans, Yaogeng Wang, Margarida L.F. Martins, Dirk R. de Waart, Olaf van Tellingen, Ji-Ying Song, Maria C. Lebre, Stéphanie van Hoppe, Els Wagenaar, Jos H. Beijnen, Alfred H. Schinkel
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 175, Iss , Pp 116644- (2024)
Transmembrane drug transporters can be important determinants of the pharmacokinetics, efficacy, and safety profiles of drugs. To investigate the potential cooperative and/or counteracting interplay of OATP1A/1B/2B1 uptake transporters and ABCB1 and
Externí odkaz:
https://doaj.org/article/397facf01d244b2c89255b44205a2de9
Autor:
David Damoiseaux, Frédéric Amant, Jos H. Beijnen, Shelby Barnett, Gareth J. Veal, Alwin D. R. Huitema, Thomas P. C. Dorlo
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 12, Pp 1931-1944 (2023)
Abstract Limited information is available concerning infant exposure and safety when breastfed by mothers receiving chemotherapy. Whereas defining distribution to breast milk is important to infer drug exposure, infant pharmacokinetics also determine
Externí odkaz:
https://doaj.org/article/af9a165e42b342d1ae831f5b5ee8be77
Autor:
Hinke Siebinga, Berlinda J. de Wit-van der Veen, Jos H. Beijnen, Marcel P. M. Stokkel, Thomas P. C. Dorlo, Alwin D. R. Huitema, Jeroen J. M. A. Hendrikx
Publikováno v:
EJNMMI Physics, Vol 10, Iss 1, Pp 1-18 (2023)
Abstract Background Prediction of [177Lu]Lu-HA-DOTATATE kidney and tumor uptake based on diagnostic [68Ga]Ga-HA-DOTATATE imaging would be a crucial step for precision dosing of [177Lu]Lu-HA-DOTATATE. In this study, the population pharmacokinetic (PK)
Externí odkaz:
https://doaj.org/article/7d39074066094585b56c1d2b07482192
Autor:
Emilie C H Breekveldt, Berbel L M Ykema, Alwin D R Huitema, Jourik A Gietema, Jos H Beijnen, Petur Snaebjornsson, Michael Schaapveld, Flora E van Leeuwen, Hilde Rosing, Monique E van Leerdam, CATCHER study working group
Publikováno v:
PLoS ONE, Vol 19, Iss 11, p e0312994 (2024)
Testicular cancer survivors (TCS) treated with platinum-based chemotherapy have increased cancer risk. Platinum retention in healthy tissue may contribute to carcinogenesis. We assessed total platinum concentrations in plasma, urine, and normal colon
Externí odkaz:
https://doaj.org/article/14543b93e99a4952b97ed838006ebac9
Autor:
David Damoiseaux, Alfred H. Schinkel, Jos H. Beijnen, Alwin D. R. Huitema, Thomas P. C. Dorlo
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 1, Pp n/a-n/a (2024)
Abstract First‐in‐human dose predictions are primarily based on no‐observed‐adverse‐effect levels in animal studies. Predictions from these animal models are only as effective as their ability to predict human results. To narrow the gap bet
Externí odkaz:
https://doaj.org/article/4492d5c59a174fd3b85d7757ccdc1918
Autor:
Karen de Jong, David Damoiseaux, Dick Pluim, Hilde Rosing, Jos H. Beijnen, Hans van Thienen, Thomas P.C. Dorlo, Alwin D.R. Huitema, Frédéric Amant
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 166, Iss , Pp 115354- (2023)
Nivolumab is an immunotherapeutic monoclonal antibody (mAb) that is used for the treatment of several types of cancer. The evidence on its use during lactation is lacking. Here, we report on a 39-year-old woman with metastasized melanoma who was trea
Externí odkaz:
https://doaj.org/article/a6d2187b2f694b489900d86979fdf8cf
Autor:
Nancy H.C. Loos, Irene A. Retmana, Jamie Rijmers, Yaogeng Wang, Changpei Gan, Maria C. Lebre, Rolf W. Sparidans, Jos H. Beijnen, Alfred H. Schinkel
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 166, Iss , Pp 115304- (2023)
Adagrasib (Krazati™) is the second FDA-approved specific KRASG12C inhibitor for non-small cell lung cancer (NSCLC) patients harboring this mutation. The impact of the drug efflux transporters ABCB1 and ABCG2, and the drug-metabolizing enzymes CYP3A
Externí odkaz:
https://doaj.org/article/d1dc8905ed1b43a4a3acf85b155c81d5